Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
Sangha R, Davies A, Dang NH, Ogura M, MacDonald DA, Ananthakrishnan R, Paccagnella ML, Vandendries E, Boni J, Goh YT. Sangha R, et al. Among authors: ananthakrishnan r. J Drug Assess. 2017 Aug 16;6(1):10-17. doi: 10.1080/21556660.2017.1315336. eCollection 2017. J Drug Assess. 2017. PMID: 28959500 Free PMC article.
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Goy A, Forero A, Wagner-Johnston N, Christopher Ehmann W, Tsai M, Hatake K, Ananthakrishnan R, Volkert A, Vandendries E, Ogura M. Goy A, et al. Among authors: ananthakrishnan r. Br J Haematol. 2016 Aug;174(4):571-81. doi: 10.1111/bjh.14094. Epub 2016 Apr 22. Br J Haematol. 2016. PMID: 27101934 Free article. Clinical Trial.
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.
DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS. DeAngelo DJ, et al. Among authors: ananthakrishnan r. Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925. eCollection 2017 Jun 27. Blood Adv. 2017. PMID: 29296758 Free PMC article.
Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Spunt SL, Grupp SA, Vik TA, Santana VM, Greenblatt DJ, Clancy J, Berkenblit A, Krygowski M, Ananthakrishnan R, Boni JP, Gilbertson RJ. Spunt SL, et al. Among authors: ananthakrishnan r. J Clin Oncol. 2011 Jul 20;29(21):2933-40. doi: 10.1200/JCO.2010.33.4649. Epub 2011 Jun 20. J Clin Oncol. 2011. PMID: 21690471 Free PMC article. Clinical Trial.
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S, Yamamoto G, Maruyama D, Asano-Mori Y, Kaji D, Ananthakrishnan R, Ogasawara K, Stepan L, Schusterbauer C, Rettby N, Hasskarl J, Izutsu K. Makita S, et al. Among authors: ananthakrishnan r. Cancer Med. 2022 Dec;11(24):4889-4899. doi: 10.1002/cam4.4820. Epub 2022 May 26. Cancer Med. 2022. PMID: 35619325 Free PMC article. Clinical Trial.
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC. Gandhi L, et al. Among authors: ananthakrishnan r. J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9. J Clin Oncol. 2014. PMID: 24323026 Clinical Trial.
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, Ananthakrishnan R, Quinn S, Soria JC. Sequist LV, et al. Among authors: ananthakrishnan r. J Clin Oncol. 2010 Jun 20;28(18):3076-83. doi: 10.1200/JCO.2009.27.9414. Epub 2010 May 17. J Clin Oncol. 2010. PMID: 20479403 Clinical Trial.
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Diéras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E. Awada A, et al. Among authors: ananthakrishnan r. Ann Oncol. 2013 Jan;24(1):109-16. doi: 10.1093/annonc/mds284. Epub 2012 Sep 11. Ann Oncol. 2013. PMID: 22967996 Free article. Clinical Trial.
206 results